Vascular Dementia Treatment Market
Vascular Dementia Treatment Market Size & Share 2025 to 2035
The global vascular dementia treatment market is projected to reach USD 9.99 billion by 2035, increasing from USD 6.64 billion in 2025, with a CAGR of 5.8% over the forecast period. This growth is driven by rising cases of vascular cognitive impairment (VCI), growing geriatric population, and advancements in neurological treatment.
Market Overview
| Market Aspect |
Details |
|---|---|
|
Market Value (2025) |
USD 6.64 Billion |
|
Market Value (2035) |
USD 9.99 Billion |
|
CAGR (2025-2035) |
5.8% |
|
Top 5 Countries’ Share |
64.2% |
|
Leading Players |
Novartis AG, Eisai Co., Ltd., Johnson & Johnson, Charsire Biotechnology, ProNeurogen Therapeutics, and others |
Key Market Drivers
Increasing Prevalence of Vascular Dementia
Vascular dementia, also termed vascular cognitive impairment (VCI), arises due to reduced blood supply to the brain, affecting memory, cognition, and behavior. With stroke-related complications on the rise, the demand for effective dementia treatments continues to escalate. According to WHO, dementia affects over 55 million people worldwide, and this number is expected to increase significantly due to aging populations.
Market Segmentation & Category Analysis
By Treatment Type:
| Treatment |
Market Share (2025) |
|---|---|
|
Drug-Based Treatment |
60.2% |
|
Non-Pharmacological Therapy |
39.8% |
Drug-based treatments dominate the market, as pharmaceutical advancements provide cognitive improvement and symptom management for vascular dementia patients.
By Drug Class:
| Drug Class |
Market Share (2025) |
|---|---|
|
Cholinesterase Inhibitors |
35.4% |
|
NMDA Receptor Antagonists |
29.6% |
|
Neuroprotective Agents |
20.3% |
|
Others |
14.7% |
Cholinesterase inhibitors, such as Donepezil, Rivastigmine, and Galantamine, are commonly prescribed for symptom management, while NMDA receptor antagonists aid in slowing disease progression.
By End-User:
| End-User |
Market Share (2025) |
|---|---|
|
Hospitals & Clinics |
48.9% |
|
Rehabilitation Centers |
34.6% |
|
Homecare Settings |
16.5% |
Hospitals and clinics remain the primary treatment centers, but homecare adoption is increasing due to personalized patient care trends.
Regional Insights & Growth Opportunities
United States:
- Accounts for 38.2% of the market, driven by an aging population and strong healthcare infrastructure.
- Increased FDA approvals for dementia-related drugs are further fueling market expansion.
Europe:
- Holds 24.1% of the market, led by Germany, France, and the UK.
- Government-funded dementia awareness programs and expansion of Alzheimer’s research boost market growth.
Asia-Pacific:
- Expected to grow at CAGR 6.3%, with China, Japan, and India leading due to rising healthcare investments and growing dementia cases.
- Initiatives such as Japan’s National Dementia Strategy support market penetration.
Challenges & Market Restraints
- Limited curative treatments, as most drugs provide only symptom relief rather than disease reversal.
- High costs of advanced drug formulations, limiting accessibility in low-income regions.
- Regulatory hurdles and approval delays affecting drug commercialization.
Competitive Landscape & Recent Developments
Leading players in the vascular dementia treatment market are focusing on new drug developments, strategic collaborations, and innovative treatment options.
Recent Developments:
- Novartis AG announced Phase 3 clinical trials for an experimental vascular dementia treatment aimed at slowing disease progression.
- Eisai Co., Ltd. partnered with a biotechnology firm to develop next-generation cognitive impairment therapies.
- Charsire Biotechnology received breakthrough designation for BAC, a soybean-based neuroprotective agent targeting vascular dementia symptoms.
Frequently Asked Questions (FAQs)
- What is the projected market size of vascular dementia treatment by 2035?
- The market is expected to reach USD 9.99 billion by 2035.
- What is the market CAGR from 2025 to 2035?
- The market is projected to grow at a CAGR of 5.8%.
- Which region holds the largest market share?
- The U.S. leads the market with a 38.2% share.
- What are the key challenges affecting market growth?
- High treatment costs, lack of curative therapies, and regulatory barriers.
- Who are the leading players in the vascular dementia treatment market?
- Novartis AG, Eisai Co., Ltd., Charsire Biotechnology, ProNeurogen Therapeutics, and others.
Take Action Now!
Contact us today to access the full report and gain strategic insights to expand your business!